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Abstract
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Stem cell replacement is providing hope for many degenerative diseases that lack effective
therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of
the central nervous system. Transplantation of neural stem cells or mesenchymal stem cells is a
potential therapy for MS thanks to their capacity for cell repopulation as well as for their
immunomodulatory and neurotrophic properties. Induced pluripotent stem cell (iPSC), an
emerging cell source in regenerative medicine, is also being tested for the treatment of MS.
Remarkable improvement in mobility and robust remyelination have been observed after
transplantation of iPSC-derived neural cells into demyelinated models. Direct reprogramming of
somatic cells into induced neural cells, such as induced neural stem cells (iNSCs) and induced
oligodendrocyte progenitor cells (iOPCs), without passing through the pluripotency stage, is an
alternative for transplantation that has been proved effective in the congenital hypomyelination
model. iPSC technology is rapidly progressing as efforts are being made to increase the efficiency
of iPSC therapy and reduce its potential side effects. In this review, we discuss the recent advances
in application of stem cells, with particular focus on induced stem/progenitor cells (iPSCs, iNSC,
iOPCs), which are promising in the treatment of MS.
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1. Introduction
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Multiple sclerosis (MS) is a common neurological disorder that targets white matter in the
central nervous system (CNS), i.e., brain and spinal cord [1, 2]. MS remains one of the
major causes of disability in young adults. Globally, the median estimated prevalence of MS
is 30 per 100,000 and the median estimated incidence of MS is 2.5 per 100,000, with rates
varying widely in different regions [3]. While the exact etiology is unknown, an aberrant
immune response against CNS antigens, especially the activation of T helper cells, is
thought to play a critical role in this disease [4]. MS is characterized by a cascade of
pathological events ranging from inflammatory cell infiltration, demyelination in multiple
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areas of the CNS, axonal degeneration, and neuron and oligodendrocyte loss [5]. The
diagnosis of MS is based on clinical dysfunction and radiological abnormalities distributed
throughout the CNS. Current therapeutic methods include relapse treatment, diseasemodifying treatment and treatment of symptoms [6–8]. Drugs such as interferon-β,
fingolimod and natalizumab can slow disease progression and reduce relapse risk, but they
cannot rectify the imbalanced immune response or repair demyelinated axons and impaired
neural cells [9–15].

Author Manuscript

Because of their self-renewal and differentiation ability, stem cells have been recently
proposed as a promising therapy for various degenerative disorders, including MS. Neural
stem cells (NSCs) and mesenchymal stem cells (MSCs) are the most common stem cell
types used in the treatment of MS. Studies have demonstrated that injection of NSCs or
MSCs can alleviate neurological dysfunction and promote remyelination in experimental
autoimmune encephalomyelitis (EAE), a widely used animal model of MS [16, 17]. It has
been shown that the therapeutic effects of NSCs and MSCs are due to their neural cell
repopulation and immunomodulatory properties, which make stem cell therapy more
effective than current drugs. Not only can they halt the inflammatory demyelinating process
in CNS, but they also differentiate into neurons and oligodendrocytes, the myelinating cells
in CNS, to repair damaged tissues.
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Eight years ago, a method of preparing another kind of stem cells, induced pluripotent stem
cells (iPSCs), was developed by Yamanaka et al. [18]. Mouse somatic cells were
reprogrammed into iPSCs by the introduction of four reprogramming factors. Soon
afterward, iPSCs were also successfully generated from cells of MS patients [19, 20].
Amelioration of disability and myelin regeneration were observed after transplantation of
iPSCs–derived NSCs and oligodendrocyte progenitor cell (OPCs) into EAE mice and other
demyelinated animal models [21, 22]. Compared with other stem cells, iPSCs have the great
advantage of being obtained from the patient’s somatic cells, thus avoiding both the risk of
transplant rejection and ethical concerns. It is expected that iPSCs derived from MS patients
will differentiate into neural lineages and tissues in vitro for disease modeling,
pathomechanism exploration, drug testing and will then be transplanted into the patient to
repair demyelinated lesions. A significant effort is being made to achieve that goal. Here we
discuss the recent advances in stem cell therapy for MS, focusing on iPSC-based stem cell
therapy.

2. Application of NSCs and MSCs in EAE
Author Manuscript

Before the development of iPSCs, other types of stem cells, NSCs and MSCs in particular,
were studied in EAE mice [23, 24]. Convincing results have been observed and mechanisms
underlying their effects have been studied, providing a strong basis for the potential use of
iPSCs in demyelinating diseases. We will therefore first discuss recent progress in the
application of NSCs/MSCs in EAE.
2.1. NSCs and EAE
NSCs are multipotent cells that can be obtained from multiple tissues, including embryo,
bone marrow, fetal and adult nervous systems [25]. When NSCs were injected
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intraventricularly into Lewis EAE rats to test their potential effects on the acute phase of
MS, these cells attenuated the clinical severity of EAE and CNS inflammation [26, 27].
Further, NSCs were also injected both intravenously (i.v.) and intracerebroventricularly
(i.c.v.) into myelin oligodendrocyte glycoprotein (MOG) 35–55 peptide-induced EAE mice,
and these cells were located exclusively in the lesioned areas of the CNS, where they
effectively promoted remyelination and functional recovery [28].

Author Manuscript

In attempting to improve NSC transplantation, its therapeutic mechanism has been
extensively investigated. NSC transplantation was originally viewed as a means of cell
replacement based on their capacity to differentiate into myelin-forming cells and neurons
[28]. In addition, a paracrine mechanism might also be involved in the beneficial effects of
NSCs, as, for example, injected NSCs induced an upregulation of growth factors such as
brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF) and promoted
proliferation and differentiation of endogenous OPCs [28]. Moreover, transplanted NSCs
might promote blood-brain barrier (BBB) integrity and attenuate CNS inflammatory
responses, e.g., decreased expression of intercellular adhesion molecule and leukocyteactivating factor, inhibited lymphocyte proliferation and CNS infiltration [29, 30]. NSCs also
induced apoptosis of infiltrating CD4+ T cells and increased the percentage of regulatory T
cells, thus protecting neural tissues from inflammatory damage and reducing neurological
disability [29].
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Various modified methods have been tested to enhance the efficacy of NSC transplantation.
For example, a great improvement in functional recovery was achieved by pre-treating
MOG-induced EAE mice with osthole, a natural coumarin with a broad spectrum of
pharmacological activities, including anti-inflammation, immunomodulation, and
neuroprotection [31]. Similar results were also obtained by transfecting NSCs with IL-10, a
potent immunomodulatory cytokine [32], and Neurotrophin 3, a neurotrophic factor that
promotes neuron and oligodendrocyte development and survival [33]. Using in vivo MRI
tracking analysis, studies have demonstrated that inflammatory signals in the CNS, such as
increased concentrations of chemokines, attracted transplanted cells into the demyelinated
areas [34, 35]. Thus, transfection of NSCs with a chemokine receptor, CCR-5, significantly
enhanced the number of transplanted NSCs and their speed in reaching demyelinated foci,
resulting in improvement of neurological function [36]. Moreover, after transplanting NSCs
with Olig2, a greater number of NSCs differentiated into OPCs, making the therapy more
effective [37].
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NSC transplantation has proved to be a promising approach for different EAE models. With
the development of iPSC technology, generation of induced NSCs (iNSCs) from human and
mouse somatic cells by directly reprogramming with a single transcription factor (TF), or a
set of them, is providing new avenues for MS treatment, which will be discussed in 4.1.
2.2. MSCs and EAE
MSCs, another type of multipotent cells, have been found in virtually all tissues, including
bone marrow (BM) and adipose tissue [23]. Two early studies demonstrated that
transplanted BM-MSCs alleviated pathological features and improved functional recovery in
both myelin proteolipid protein (PLP)-induced and MOG-induced EAE mice [38, 39]; more
Curr Stem Cell Res Ther. Author manuscript; available in PMC 2016 May 06.
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recently, other studies showed that MSCs from BM and adipose tissue reduced infiltration of
inflammatory cells into the CNS [40–42]. Moreover, MSCs from MOG-induced EAE mice
had similar biological properties as MSCs from healthy donors, making possible the use of
autologous MSCs from MS patients [43]. To improve the effects of MSCs therapy, different
modified methods were tested. For instance, inhibition of autophagy in MSCs by
knockdown of Becn1 significantly improved their therapeutic effects [44].
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The therapeutic mechanism of MSCs in alleviating the clinical course of EAE is still
controversial. It was found that the majority of transplanted MSCs migrated to lymphoid
organs and induced a T-cell unresponsive state in MOG-induced EAE mice [38]. By using
enhanced green fluorescent protein (eGFP) to track MSCs, Gerdoni et al. did not find any
GFP+ neural cells within the brain parenchyma [17], indicating that MSCs might exert their
beneficial effects by modulating the immune system, but not by neural cell repopulation [45,
46]. Nevertheless, MSCs also promoted endogenous neural generation though BDNF
secretion [39]. Thus, MSCs exerted therapeutic effects on EAE not only through their
immunomodulation function, but also their neurotrophic capacity.

3. Application of iPSC-based cell therapy
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The breakthrough innovation of iPSCs has sparked an enormous global effort to carry out
disease modeling, drug screening and regenerative therapy. The reprogrammed cells have
similar morphologies to embryonic stem cells (ESCs) and can differentiate into cell types
representing all three embryonic germ layers [18]. Subsequent successful attempts to
generate human iPSCs from both healthy and diseased individuals have brought us several
steps closer to clinical application [47–49]. This technology makes it possible for pluripotent
cells reprogrammed from the MS patient’s somatic cells to differentiate in vitro into the
desired cell lineages or tissues for both pathophysiological research and in vivo cell-based
treatment. The therapeutic effects of these cells have been tested in EAE and other
demyelinated model systems, as summarized in Table 1.
3.1. IPSCs can differentiate into oligodendrocyte lineage in vitro
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Successful differentiation of iPSCs into oligodendrocyte lineage is fundamental for the
treatment of MS. In 2010, Tokumoto compared the differentiating ability of mouse iPSCs
with ESCs. After induction, OPC marker A2B5 positive cells and oligodendrocyte-specific
cell surface marker O4 positive cells were observed in both iPSC- and ESC-derived cells
[50]. Human iPSCs were first induced to differentiate to oligodendrocytes in 2011 [51].
Fibroblast-derived iPSCs from healthy adults were treated with epidermal growth factordependent differentiation protocol and eventually differentiated to O4+ oligodendrocytes.
However, the efficiency was low (less than 0.01%). Fibroblasts from relapsing-remitting
multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) patients were
also reprogrammed into iPSCs, and these MS-iPSCs successfully differentiated into mature
neurons, astrocytes and oligodendrocytes with normal karyotypes. The MS-iPSC derived
neurons were electrophysiologically functional, and the oligodendrocytes displayed positive
staining for myelin basic protein (MBP) and O4. Generation of neural cells from MS-iPSCs
in vitro was an important step toward achieving individualized treatment [19].

Curr Stem Cell Res Ther. Author manuscript; available in PMC 2016 May 06.

Xie et al.

Page 5

3.2. Effects of iPSC-derived NSCs on EAE

Author Manuscript
Author Manuscript

Given the therapeutic effects of subventricular zone- and BM-derived NSCs on EAE [28,
52], it has been proposed that iPSC-derived NSCs have similar effects. To test this, Laterza
et al. generated NSCs from mouse iPSCs and transplanted them into MOG-induced EAE
mice intrathecally. The NSC-treated EAE mice showed clinical amelioration, with reduced
demyelinated areas and axonal damage in the spinal cord. However, the majority of
transplanted NSCs did not differentiate into oligodendrocyte lineages in vivo, indicating that
they did not participate in remyelination directly. Nevertheless, iPSC-derived NSCs
promoted the survival and differentiation of endogenous myelin-forming cells by secreting a
specific neurotrophin: leukaemia inhibitory factor. The trophic effect mediated by NSCs also
improved BBB integrity, thus limiting the CNS-confined inflammation [21]. Given that
myelin damage is often caused by CNS inflammation, exerting neuroprotective and
neurotrophic effect within an inflammatory environment makes iPSC-NSCs a promising cell
source for treating MS.
3.3. Effects of iPSC-derived OPCs on chemically-induced demyelinated and congenital
hypomyelination models
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In addition to iPSC-derived NSCs, another common cell source for transplantation was
iPSC-derived OPCs. The myelin-forming capacity of iPSC-derived OPCs was examined in
vivo by injecting them into the demyelinated corpus callosum of cuprizone-fed mice; the
implanted OPCs developed into mature MBP+ oligodendrocytes that contributed to the
remyelination of the corpus callosum axons [53]. OPCs derived from human iPSCs were
also transplanted into the lysolecithin-induced demyelinated rat optic chiasm [54]. Obvious
remyelination was revealed by luxol fast blue myelin-specific staining after transplantation.
The visual evoked potential recording also reflected functional improvement. The
transplanted cells differentiated into mature oligodendrocytes and integrated within the
chiasm, contributing to remyelination and functional recovery.
Human iPSC-derived OPCs were also tested in shiverer mouse, a genetic model of
congenital hypomyelination [22]. Mice transplanted with iPSC-OPCs exhibited markedly
improved survival, with reduced mortality over a 9-month period of observation. Robust
donor-derived myelination, with a higher proportion of ensheathed axons in recipient brains,
was revealed by confocal images [22]. MS-iPSC-derived OPCs were also injected into
shiverer mice to evaluate their myelinogenic ability. After 16 weeks, human MBP+
oligodendrocytes were found diffusely throughout the engrafted corpus callosum, and about
30% of host mouse axons were ensheathed [20]. Together, these results provided direct
evidence for the myelinogenic effect of iPSC-derived OPCs in vivo.
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3.4. Modifications to improve the generation and migration of iPSC-derived OPCs
Although iPSC-derived OPCs can differentiate into mature oligodendrocytes and form
myelin in vivo, it is difficult to acquire large numbers of autologous OPCs [55]. Modifying
the protocols to generate sufficient iPSC-OPCs in a relatively short time is crucial. In an
attempt to do so, Douvaras et al. induced OPCs from iPSCs by dual inhibition of SMAD
signaling in adherent cultures and addition of retinoic acid and/or sonic hedgehog; 44%-70%
OPCs were obtained after 75 days of differentiation, compared with the minimum of 120
Curr Stem Cell Res Ther. Author manuscript; available in PMC 2016 May 06.
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days previously required [20]. Furthermore, it was found that the differentiation rate of
iPSCs-derived OPCs into O4+ oligodendrocytes was increased by overexpression of p27,
and the differentiation efficiency was enhanced over eightfold compared with the control
experiments [56].
While iPSC-derived OPCs have the ability to generate and restore the myelin sheath, they
have limited capacity to migrate along the axons [53]. To increase the migratory capacity of
these cells, overexpression of sialyltransferase X (STX) was induced in iPSC-derived OPCs
via lentiviral transduction, after which transfected cells were injected into the cuprizone-fed
demyelinated mice to examine their migratory and myelinogenic behavior. At 3 weeks after
implantation, STX-transfected OPCs survived and repopulated the corpus callosum along its
entire width on the unilateral side of the injection. A significant increase in migration along
the axons was revealed compared with control OPCs [57].

Author Manuscript

4. Direct transdifferentiation of somatic cells to NSCs and OPCs
After the successful reprogramming of somatic cells to iPSCs, a more direct lineage
conversion of fibroblasts to functional neurons by defined factors was achieved in 2010 [58].
This novel approach made it possible for a fully differentiated cell to be transformed into
another specialized cell type without passing through the pluripotency stage. Subsequently,
strategies were developed for the generation of other induced neural lineage cells using
specific sets of TFs in optimal culture conditions [59, 60].
4.1. Induced neural stem cells (iNSCs)
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In 2011, Kim et al. first showed that four Yamanaka reprogramming factors in combination
with NSC-permissive culture condition directly transformed fibroblasts to iNSCs [61]; these
iNSCs differentiated to neurons and astrocytes, but self-renewed for only 3–5 passages.
Thier et al. also generated iNSCs that could be expanded for more than 50 passages by
constitutively inducing Sox2, Klf4 and c-Myc while strictly limiting Oct4 activity [62]. The
iNSCs not only had a similar genome-wide transcriptional profile compared to brain-derived
NSCs, but they could also differentiate into neurons, astrocytes, and oligodendrocytes.
Tripotent, self-renewing iNSCs were also induced using a combination of TFs: Brn4/Pou3f4,
Sox2, Klf4, c-Myc, plus E47/Tcf3 [63]. Furthermore, Ring et al. reported the generation of
iNSCs by direct reprogramming with a single TF: Sox2. The implanted Sox2-induced iNSCs
survived and was integrated into mouse brains and did not generate tumors [64].
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The effects of iNSCs were also examined in a congenital hypomyelination model. Lujan et
al. injected iNSCs that were eGFP positive into the neonatal brain of shiverer mouse [65].
Ten weeks after transplantation, eGFP+ cells and MBP+ myelin sheaths were observed in
white-matter tracts of the cerebellum. This result indicates that iNSCs differentiated into
myelinating oligodendrocytes and restored myelin sheaths.
4.2. Induced oligodendrocyte progenitor cells (iOPCs)
Najm et al. [66] found that forced expression of sets of 8 or 3 defined TFs could directly
reprogram mouse fibroblasts into myelinogenic iOPCs, obviating the use of iPSCs. The 8
TFs (Olig1, Olig2, Nkx2.2, Nkx6.2, Sox10, ST18, Gm98 and Myt1) or 3 TFs (Nkx6.2,
Curr Stem Cell Res Ther. Author manuscript; available in PMC 2016 May 06.
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Sox10, Olig2)-induced mouse fibroblast globally expressed OPC genes and could
differentiate into cells with a typical morphology of oligodendrocytes. The iOPCs generated
characteristically MBP+ myelin sheaths after being transplanted into organotypic slice
cultures, which provided a complex 3D tissue representative of the CNS. Compact myelin
sheaths around dorsal column axons were also restored. Furthermore, the authors found that
the efficiency of generating functional iOPCs was enhanced by increasing the viral titer of
the TFs [66].
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Consistent with Najm’s study, Yang et al. [67] also generated iOPCs from mouse and rat
fibroblasts using 3 TFs (Sox10, Olig2 and Zfp536). These iOPCs exhibited properties of
bona fide OPCs; they gave rise to MBP+ cells that showed mature oligodendrocytic
morphologies and myelinated the axons of dorsal root ganglion neurons in vitro. When
iOPCs were injected into shiverer mouse brains, small scattered groups of MBP+ cells
forming tube-like structures that surrounded axons were detected at all injection sites of
brain. The myelin formation of transplanted iOPCs was also confirmed by ultrastructural
analysis. These results strongly indicated the myelinogenic capacity of iOPCs.
Although iNSCs and iOPCs have not been tested in EAE mice, they may be more
advantageous than other types of stem cells. First, iNSCs and iOPCs have shown their
myelinogenic ability in vitro and in vivo, which is advantageous over MSCs. Second, a
relatively simpler generation protocol makes their use less effort- and cost-consuming than
iPSCs. Last but not least, iNSCs and iOPCs are autologous cells, making them promising
candidates for individualized cell treatment compared to those derived from ES cells or stem
cells of umbilical cord blood. Certainly, the therapeutic effects of iNSCs and iOPCs on
EAE/MS need to be evaluated by further studies.
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5. Therapeutic mechanisms of stem cells
Although spontaneous recovery is observed in the early stage of MS, endogenous processes
of repair and remyelination are typically incomplete and ultimately fail in the setting of
recurrent episodes. Exogenous stem cell transplantation has therefore been advocated for
regenerative medicine. Accumulated studies have shown the therapeutic effects of NSCs or
MSCs on EAE. iPSC-based stem cells, including iPSCs-derived NSCs and OPCs, iNSCs,
iOPCs, have also shown their potential in treatment of EAE/MS. The underlying
mechanisms for the beneficial effects of stem cells may include: 1) as an exogenous source
of neuron/oligodendrocyte repopulation; 2) immunomodulation, thus converting the CNS
microenvironment from a hostile to a supportive one; and 3) neurotrophic effects, thus
promoting endogenous neuron/oligodendrocyte differentiation and regeneration.
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In the acute phase of EAE, the immunoregulatory property of stem cells protects tissue from
attacks of abnormal inflammation; in the chronic phase, stem cells secrete neurotrophic
factors to promote endogenous remyelination. Furthermore, NSCs also produce matrix
metallo proteinases that degrade extracellular matrix and cell surface molecules that impede
axonal regeneration, thus enabling axons to extend through the glial scar [68]. Meanwhile,
stem cells also provide exogenous neurons and oligodendrocytes to restore myelin and
axons.
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6. Challenges confronting clinical application of iPSC-derived stem cells in
MS
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IPSCs are similar to ESCs in morphology and ability to proliferate and differentiate, which
makes them a promising candidate for regenerative medicine. The fact that they are easily
obtained from somatic cells makes their use free from ethical concerns. Furthermore,
patient-derived iPSCs are immunologically privileged for transplantation, eliminating the
need for lifelong immunosuppressive drugs. These advantages make iPSC-derived stem cells
attractive for clinical application in MS treatment. However, many obstacles need to be
surmounted before this can become a reality. These obstacles include the genomic instability
of iPSCs, which is potentially tumorigenic. Some TFs, such as c-Myc, used to generate
iPSCs are potent oncogenes [69]. In addition to these safety concerns, current methods for
generating iPSCs are inefficient and time-consuming, and there remains a tremendous gap
between generation of iPSC-derived stem cells for research and for therapeutic purposes [70,
71].
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In addition to the common challenges with iPSCs, MS adds three more challenges to the
complex, in vivo microenvironment surrounding transplanted iPSC-derived stem cells in
CNS foci: 1) persistent CNS inflammation, including BBB disruption, high numbers of
infiltrating immune cells, and increased levels of proinflammatory cytokines, nitric oxide
and other cytotoxic molecules, etc. [72, 73]; 2) loss of trophic support for both
oligodendrocytes and neurons [74]; and 3) accumulation of neuroregeneration inhibitors,
including myelin-associated glycoprotein, oligodendrocyte myelin glycoprotein and Nogo A
[75, 76]. The vicious cycle involving these mechanisms results in a hostile
microenvironment, which not only leads to the failure of endogenous remyelination, but
would also inhibit for the regenerating capacity of transplanted (exogenous) cells.
Approaches to convert the hostile CNS microenvironment to a supportive one needs to be
further studied for future MS therapy.

7. Conclusions
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In this review we summarized the recent advances in application of iPSC-derived stem cells
in treatment strategies for MS/EAE (summarized in Fig. 1). While NSCs and MSCs have
long been tested as an effective MS/EAE therapy, the successful generation of iPSCs from
somatic cells opens up a new era of stem cell therapy. The advantages of being easily
obtained from the patient’s own tissue and being well tolerated make iPSC-derived stem
cells, especially iNSCs and iOPCs, the most suitable candidates for individualized cell
replacement therapy. After being examined in EAE and other demyelinated models, iPSCderived stem cells have shown great potential in the treatment of MS. Although there are still
many problems to be solved before clinical application, we anticipate that, with the dramatic
progress in the iPSC field, these challenges can be met, making iPSC-derived stem cell
transplantation an autologous, safe and highly effective therapy for MS.
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BBB

blood-brain barrier

BDNF

brain-derived neurotrophic factor

BM

bone marrow

CNS

central nervous system

EAE

experimental autoimmune encephalomyelitis

eGFP

enhanced green fluorescent protein

ESC

embryonic stem cell

iNSC

induced neural stem cell

iOPC

induced oligodendrocyte progenitor cell

iPSC

induced pluripotent stem cell

MBP

myelin basic protein

MOG

myelin oligodendrocyte glycoprotein

MS

multiple sclerosis

MSC

mesenchymal stem cell

NGF

nerve growth factor

NSC

neural stem cell

OPC

oligodendrocyte progenitor cell

PLP

proteolipid protein

PPMS

primary progressive multiple sclerosis

RRMS

relapsing remitting multiple sclerosis

STX

sialyltransferase X

TF

transcription factor
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Fig. 1. Application of induced stem cells in treatment of MS
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iPSCs: induced pluripotent stem cells; NSCs: neural stem cells; OPCs: oligodendrocyte
progenitor cells; iNSC: induced neural stem cell; iOPC: induced oligodendrocyte progenitor
cell.

Author Manuscript
Curr Stem Cell Res Ther. Author manuscript; available in PMC 2016 May 06.

Author Manuscript

Author Manuscript
iPSC
iPSC
iNSCs
iOPC
iOPC

OPCs

NSCs

iNSCs

iOPCs

iOPCs

iPSC

OPCs
iPSC

iPSC

OPCs

OPCs

Intermediate cells

Transplanted cells

Rat fibroblast

Mouse embryonic fibroblast

Mouse embryonic fibroblast

Mouse embryonic fibroblast

Fibroblast of PPMS patient

Human fibroblast, Human
keratinocyte

Human dermal fibroblast

Mouse embryonic fibroblast

Original cells

Congenital hypomyelination model

Congenital hypomyelination model

Congenital hypomyelination model

MOG-induced EAE

Congenital hypomyelination model

Congenital hypomyelination model

Lysolecithin-induced model

Cuprizone-induced model

Demyelinated models

Conclusions

[65]
[66]
[67]

Generated MBP+ myelin sheets in white-matter tracts of the
cerebellum
Generated compact myelin in vitro and in vivo
Differentiated into myelinating OLs and formed myelin in vivo

Restrained demyelination, promoted remyelination; Trophic effect
limited CNS-confined inflammation

[21]

[20]

Differentiated to OLs in vitro and successfully ensheathed axons in

vivo

[22]

[54]

[53]

Refs

Formed myelin in the brains of shiverer mice and increased their
survival

Improved remyelination of the optic chiasm, as well as nerve
function

Developed into mature OLs and contributed to remyelination

Author Manuscript

Summary of effective iPSC-derived cell therapies for demyelinated models

Author Manuscript

Table 1
Xie et al.
Page 15

Curr Stem Cell Res Ther. Author manuscript; available in PMC 2016 May 06.

